<DOC>
	<DOCNO>NCT00085436</DOCNO>
	<brief_summary>RATIONALE : Vaccines make patient 's dendritic cell tumor cell may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's lymphocyte kill kidney cancer cell . Interferon alfa may interfere growth cancer cell . Combining vaccine therapy interleukin-2 interferon alfa may kill tumor cell . PURPOSE : This phase II trial study well give vaccine therapy together interleukin-2 interferon alfa work treat patient metastatic renal cell carcinoma ( kidney cancer ) .</brief_summary>
	<brief_title>DC Vaccine Combined With IL-2 IFNα-2a Treating Patients With mRCC</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response rate patient metastatic renal cell carcinoma treat autologous dendritic cell ( DC ) load autologous tumor lysate ( DC vaccine ) combination interleukin-2 interferon-alfa . - Determine toxicity regimen patient . Secondary - Determine , within relevant immune pathway , treatment-related , tumor-specific immune response patient treat regimen . - Correlate tumor-specific immune response objective clinical response patient treat regimen . OUTLINE : - Induction therapy : Patients undergo leukapheresis day -9 . Patients receive autologous dendritic cell ( DC ) load autologous tumor lysate ( DC vaccine ) intranodal injection day 0 14 ; interleukin-2 ( IL-2 ) IV continuously day 1-5 15-19 ; interferon-alfa ( IFN-α ) subcutaneously ( SC ) daily day 1 , 3 , 5 , 15 , 17 , 19 . - Maintenance therapy : Patients undergo leukapheresis day 33 , 61 , 89 . Patients receive DC vaccine intranodal injection day 42 , 70 , 98 ; IL-2 IV continuously day 43-47 , 71-75 , 99-103 ; IFN-α SC daily day 43 , 45 , 47 , 71 , 73 , 75 , 99 , 101 , 103 . Patients follow every 3 month . PROJECTED ACCRUAL : A total 18-33 patient accrue study .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histologically confirm metastatic renal cell carcinoma measurable disease . Tumor tissue available properly store lysate preparation . Patients must least 4 week last immunotherapy , radiation , surgery chemotherapy ( 6 week nitrosureas ) recover ill effect . Karnofsky Performance Status ≥60 % Life expectancy ≥ twelve week Adequate end organ function : Hematological : ANC ≥ 1000cells/μL , platelet ≥ 75,000/μL , hemoglobin ≥ 8.5 g/dl Liver : AST &lt; 2 x ULN ( upper limit normal ) unless due metastasis &lt; 5 x ULN , serum total bilirubin &lt; 2 x ULN ( except patient Gilbert 's Syndrome ) Renal : serum creatinine &lt; 2.0 x ULN . Pulmonary : FEV1 &gt; 2.0 liter &gt; 75 % predict height age . Cardiac : No evidence congestive heart failure , symptom coronary artery disease , myocardial infarction le 6 month prior entry , serious cardiac arrhythmia . Patients 40 previous myocardial infarction great 6 month prior entry require negative low probability cardiac stress test cardiac ischemia . CNS : No history brain metastasis . Women lactate , childbearing age , negative pregnancy test within two week entry study . Appropriate Contraception sex EXCLUSION CRITERIA : Patients may treat previously IL2 , IFNα autologous vaccine . Concomitant second malignancy except nonmelanoma skin cancer , non invasive cancer cervical CIS , superficial bladder cancer without local recurrence , breast CIS . In patient prior history invasive malignancy , less five year complete remission Positive serology HIV , hepatitis B hepatitis C , Significant comorbid illness uncontrolled diabetes active infection would preclude treatment regimen . Use corticosteroids immunosuppression ( patient take steroid , least 4 week must pass since last dose ) . History autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
</DOC>